SPY756.10−0.49%QQQ684.00−0.92%BTC/USD73,684.00−0.33%DIA524.23−0.04%GLD365.88+0.19%TLT80.87−0.06%

BridgeBio Pharma Inc

BBIONASDAQ

Trade with Public

$79.54

0.871.11%

Last update: Nov 11, 4:13 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

BridgeBio Pharma (BBIO) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for BridgeBio Pharma (BBIO) stock.

Analyst Consensus — 25 Analysts

25Buy

# Analysts25

Latest Upgrades and Downgrades for BridgeBio Pharma Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$106→$108
—	TD Cowen	Tyler Van Buren	PT Cut	Buy	$110→$100
—	Morgan Stanley	Sean Laaman	PT Raise	Overweight	$87→$88
—	Morgan Stanley	Sean Laaman	PT Cut	Overweight	$97→$87
—	Citigroup	Eric Joseph	PT Cut	Neutral	$94→$91
—	Piper Sandler	Biren Amin	PT Raise	Overweight	$115→$120
—	UBS	Joon Lee	Assumes	Buy	$82→$92
—	Barclays	Eliana Merle	PT Cut	Overweight	$157→$156
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$120
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$120
—	Mizuho	Salim Syed	PT Raise	Outperform	$96→$110
—	Truist Securities	Danielle Brill	PT Raise	Buy	$102→$107
—	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$104→$106
—	JP Morgan	Anupam Rama	PT Raise	Overweight	$100→$111
—	B of A Securities	Geoff Meacham	PT Raise	Buy	$101→$104
—	TD Cowen	Tyler Van Buren	PT Raise	Buy	$95→$110
—	Morgan Stanley	Sean Laaman	PT Cut	Overweight	$98→$97
—	Piper Sandler	Biren Amin	PT Raise	Overweight	$111→$115
—	Wells Fargo	Derek Archila	PT Raise	Overweight	$98→$102
—	Citigroup	Eric Joseph	PT Raise	Neutral	$82→$93

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) Stock Price Target 2026

Latest Upgrades and Downgrades for BridgeBio Pharma Stock

BridgeBio Pharma (BBIO) Stock Price Target 2026

Latest Upgrades and Downgrades for BridgeBio Pharma Stock

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108

PRO
TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

PRO
Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

PRO
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108

PRO
TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

PRO
Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

PRO
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) Stock Price Target 2026

Latest Upgrades and Downgrades for BridgeBio Pharma Stock

BridgeBio Pharma (BBIO) Stock Price Target 2026

Latest Upgrades and Downgrades for BridgeBio Pharma Stock

Analyst Ratings News

PROCanaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108

PROTD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100

PROMorgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88

PROMorgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

PROCitigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

PROPiper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

People Also Watch

People Also Watch

Analyst Ratings News

PROCanaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108

PROTD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100

PROMorgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88

PROMorgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

PROCitigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

PROPiper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108

PRO
TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

PRO
Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

PRO
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108

PRO
TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88

PRO
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87

PRO
Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

PRO
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120